| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Director | Common Stock | 66.8K | $2.41M | $36.00 | May 5, 2023 | Direct |
| ADC Therapeutics SA | Director | Common Shares | 107K | $383K | $3.58 | Jun 13, 2025 | Direct |
| HALOZYME THERAPEUTICS, INC. | Director | Option to Purchase Common Stock | 11.4K | $158K | $13.87 | May 5, 2023 | Direct |
| Aprea Therapeutics, Inc. | Director | Common Stock | 1.05K | $1.69K | $1.62 | Jun 5, 2025 | Direct |
| Aprea Therapeutics, Inc. | Director | Stock Options (Right to Buy) | 4.19K | Jun 5, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ADCT | ADC Therapeutics SA | Jun 13, 2025 | 1 | -$45.1K | 4 | Jun 17, 2025 | Director |
| APRE | Aprea Therapeutics, Inc. | Jun 5, 2025 | 2 | $0 | 4 | Jun 9, 2025 | Director |
| ADCT | ADC Therapeutics SA | Jun 3, 2025 | 1 | $0 | 4 | Jun 5, 2025 | Director |
| ADCT | ADC Therapeutics SA | Jun 17, 2024 | 1 | -$20.2K | 4 | Jun 18, 2024 | Director |
| ADCT | ADC Therapeutics SA | Jun 13, 2024 | 1 | $0 | 4 | Jun 14, 2024 | Director |
| ADCT | ADC Therapeutics SA | Jan 2, 2024 | 0 | $0 | 3 | Jan 2, 2024 | Director |
| APRE | Aprea Therapeutics, Inc. | Aug 23, 2023 | 1 | $0 | 4 | Aug 24, 2023 | Director |
| APRE | Aprea Therapeutics, Inc. | Aug 23, 2023 | 0 | $0 | 3 | Aug 24, 2023 | Director |
| HALO | HALOZYME THERAPEUTICS, INC. | May 5, 2023 | 2 | $0 | 4 | May 9, 2023 | Director |
| HALO | HALOZYME THERAPEUTICS, INC. | May 5, 2022 | 1 | $0 | 4 | May 6, 2022 | Director |
| HALO | HALOZYME THERAPEUTICS, INC. | Aug 25, 2021 | 1 | -$1.44M | 4 | Aug 25, 2021 | Director |